No Data
Shandong Buchang Pharmaceuticals (603858.SH): The marketing authorization holder of An Gong Niu Huang Wan has been changed from Liaoning Han Cao Tang to Shandong Buchang Pharmaceuticals.
On March 18, Gelonghui reported that Shandong Buchang Pharmaceuticals (603858.SH) announced that it recently received the "Approval Notice for Supplementary Application of Pharmaceuticals" issued by the National Medical Products Administration, agreeing to change the marketing authorization holder of An Gong Niu Huang Wan from Liaoning Hancatang to Shandong Buchang Pharmaceuticals. The official change of the marketing authorization holder of An Gong Niu Huang Wan to Shandong Buchang Pharmaceuticals is beneficial for expanding the company's Business, enriching the company's product line, and strengthening market competitiveness. It will not have a significant impact on the company's current Operation.
Shandong Buchang Pharmaceuticals (603858.SH): The controlling subsidiary plans to establish a subsidiary Suzhou Hepu Medical Instruments.
On March 18, Glonghui reported that Shandong Buchang Pharmaceuticals (603858.SH) announced that, according to the company's overall development plan, to promote the operation and development of its holding subsidiary Shanghai Hupuh Medical Technology Co., Ltd. (referred to as "Shanghai Hupuh Medical Technology"), Shanghai Hupuh Medical Technology plans to jointly invest with Suzhou Industrial Park Mingpu Medical Technology Co., Ltd. (referred to as "Mingpu Medical") to establish a new company, Suzhou Hupuh Medical Instruments Co., Ltd. (tentative name, final name subject to approval by the industrial and commercial department) (referred to as "Suzhou Hupuh Medical Instruments"). The registered capital of Suzhou Hupuh Medical Instruments is 2 million yuan, and Shanghai Hupuh Medical Technology invests.
Buchang Pharmaceuticals Gets Approval for Chickenpox Vaccine Clinical Trial
Shandong Buchang Pharmaceuticals (603858.SH): The clinical trial for the freeze-dried human rabies vaccine (human diploid cells) has received an acceptance notification.
On March 12, Gelonghui reported that Shandong Buchang Pharmaceuticals (603858.SH) announced that its holding subsidiary, Zhejiang Tianyuan Biological Pharmaceutical Co., Ltd., has recently received acceptance from the National Medical Products Administration for the drug registration clinical trial application of the "lyophilized human rabies vaccine (human diploid cells)" and has received the "Acceptance Notice." The indication for the lyophilized human rabies vaccine (human diploid cells) is that after vaccination with this vaccine, the body can produce immunity against rabies virus, and it is used for the prevention of rabies.
Shandong Buchang Pharmaceuticals (603858.SH): The live attenuated varicella vaccine has obtained the drug clinical trial approval notice.
On March 12, Gelonghui reported that Shandong Buchang Pharmaceuticals (603858.SH) announced that its holding subsidiary, Zhejiang Tianyuan Biotechnology Co., Ltd., received the "Notice of Approval for Clinical Trials" issued by the National Medical Products Administration for the research variety "Varicella Attenuated Live Vaccine." Indication for the varicella attenuated live vaccine: after vaccination with this vaccine, it can stimulate the body to produce immunity against the varicella-zoster virus. It is used for the prevention of chickenpox.
Shandong Buchang Pharmaceuticals (603858.SH): has repurchased 0.29% of the company's shares.
On March 11, Gelonghui reported that Shandong Buchang Pharmaceuticals (603858.SH) announced that as of March 11, 2025, the company has cumulatively repurchased 3,210,530 shares through centralized bidding Trade, accounting for 0.29% of the company's total share capital, with a maximum purchase price of 15.06 yuan/share and a minimum price of 14.55 yuan/share, and the total amount paid is 47,747,958.65 yuan (excluding transaction fees).
Shandong Buchang Pharmaceuticals (SHSE:603858) Shareholders Have Endured a 15% Loss From Investing in the Stock Three Years Ago
